News & Updates

Retifanlimab plus chemo improves survival in metastatic NSCLC
Retifanlimab plus chemo improves survival in metastatic NSCLC
07 Jan 2025 byStephen Padilla

The addition of retifanlimab to platinum-based chemotherapy results in better overall survival in patients with metastatic nonsmall cell lung cancer (NSCLC), as shown in the phase III study POD1UM-304 presented at ESMO Asia 2024. Moreover, the combination treatment has a safety profile consistent with that of other checkpoint inhibitors.

Retifanlimab plus chemo improves survival in metastatic NSCLC
07 Jan 2025
T-DXd improves PFS in breast cancer with rapid progression
T-DXd improves PFS in breast cancer with rapid progression
06 Jan 2025 byStephen Padilla

Treatment with trastuzumab deruxtecan (T-DXd) results in longer progression-free survival (PFS) in patients with hormone receptor–positive, HER2-low or HER2-ultralow metastatic breast cancer (mBC) compared with physician’s choice of chemotherapy, according to the results of the phase III DESTINY-Breast06 study presented at SABCS 2024. In addition, no new safety signals have been identified.

T-DXd improves PFS in breast cancer with rapid progression
06 Jan 2025